



Medical Oncology Preauthorization: AIM Specialty Health® FAQs

Effective **June 1, 2020**, SelectHealth partners with AIM Specialty Health (AIM) to manage preauthorization requests for **intravenous and injectable medical oncology services** for commercial, Medicare, Medicaid, and Children's Health Insurance Program (CHIP) plans. All regimens, including oral and intravenous or injectable chemotherapy or immunotherapy, must be submitted to AIM for pathways adherence.

WHAT DOES THIS MEAN FOR MY PRACTICE?

When your practice prescribes a cancer treatment regimen for a patient covered by SelectHealth and submits it to AIM for review, the prescribed regimen is compared against a comprehensive database of current, evidence-based AIM Cancer Treatment Pathways. If the planned regimen does not align with an AIM Pathway, information on evidence-based alternatives may be presented for your review.

For services provided on or after **June 1, 2020**, you will need to use AIM to obtain preauthorization for intravenous and injectable medical oncology services.

Categories of intravenous and injectable oncology drugs that may require preauthorization include:

- > Chemotherapy
- > Immunotherapy
- > Supportive drugs

NOTE: SelectHealth will continue to manage preauthorization requests for oral oncology drugs. Continue to submit these requests via [PromptPA](#).

WHY IS SELECTHEALTH MAKING THIS CHANGE?

This approach helps ensure that care aligns with established evidence-based medicine. In collaboration with providers, the AIM medical oncology program will improve members' access to quality care while reducing costs associated with unnecessary or inappropriate treatment.

HOW QUICKLY WILL PREAUTHORIZATION REVIEW AND APPROVAL HAPPEN?

Requests that meet criteria receive an immediate response in the [AIM ProviderPortalSM](#) or on the phone with the AIM contact center (see below).

If a request cannot be approved immediately, the request is transferred to an oncology nurse for further review. The ordering provider has an opportunity to discuss the pending case with an AIM physician reviewer in a peer-to-peer review. No adverse determination is made until the case has been reviewed by an AIM oncologist.

HOW DO I FIND AIM TRAINING INFORMATION?

Webinars were held in April and early May with emails and letters sent to affected providers in early April. If you missed these training opportunities, you can [access and download the slides](#) from those sessions.

HOW DO I START USING AIM?

Beginning **May 18, 2020**, AIM phone lines and portal will become available. After that date, you will be using the following methods to contact AIM for services provided on or after **June 1, 2020**. Contact AIM:

- > Online 24/7 via the [AIM ProviderPortalSM](#). This fully interactive resource processes requests in real time against clinical criteria.
- > By phone at **844-377-1281** (8:00 am–5:00 pm MT).

To learn about the [AIM ProviderPortalSM](#), including the clinical appropriateness review process and features, tutorials and FAQs, pathways, and worksheets to help you gather information needed for review requests, visit [Medical Oncology Program for SelectHealth Providers](#).